Related Experiment Video
Updated: Aug 6, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
VSIG2 Promotes Osteosarcoma Cisplatin Resistance Via Activating PI3K/AKT/mTOR Pathway
Xueren Zhong1, Jing Xiang2, Xiaoyu Yang1
1Department of Spinal Surgery, Yuebei People's Hospital Affiliated to Shantou University Medical College, Shaoguan, China.
Introduction:
Chemotherapy resistance is one of the main reasons for osteosarcoma (OS) relapses. Understanding the regulatory mechanisms of cisplatin resistance is critical for developing potential therapeutic strategies for OS. This study aimed to examine the role of VSIG2 in OS chemotherapy resistance.
Methods:
Cell viability assay, colony formation assay, LDH cytotoxicity assay, and a subcutaneous xenograft model were used to explore VSIG2's role in OS cisplatin resistance in vitro and in vivo. A luciferase reporter assay was carried out to determine the pathways regulated by VSIG2. Co-Immunoprecipitation was carried out to investigate the interaction of VSIG2.
Results:
VSIG2 is upregulated in OS tissues with poor response to neoadjuvant chemotherapy. Functionally, VSIG2 promoted cisplatin resistance determined by cell models and animal models. Mechanistically, VSIG2 activated the PI3K/AKT pathway. Moreover, VSIG2 interacted with mTOR and increased p70 S6 Kinase phosphorylation. Furthermore, inhibition of mTOR significantly reversed the effect of VSIG2 on cisplatin resistance.
Discussion:
Our findings emphasize the key role of VSIG2 in chemoresistance of OS, deepening the understanding of the molecular mechanisms of OS chemoresistance generation.
Conclusion:
In summary, our findings suggested that VSIG2 may confer novel platinum resistance via activating the PI3K/AKT/mTOR pathway, providing a potential target for OS therapy.
Insights
Vesicle-associated membrane protein A (VAMP) 2 homolog 2 (VSIG2) promotes cisplatin resistance in osteosarcoma (OS). VSIG2 activates the PI3K/AKT/mTOR pathway, offering a potential therapeutic target for overcoming OS chemoresistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Chemotherapy resistance is a major cause of osteosarcoma (OS) relapse.
- Understanding cisplatin resistance mechanisms is crucial for effective OS therapeutic strategies.
Purpose of the Study:
- To investigate the role of VSIG2 in mediating chemoresistance in osteosarcoma.
- To elucidate the molecular pathways involved in VSIG2-driven cisplatin resistance.
Main Methods:
- In vitro and in vivo experiments including cell viability, colony formation, and xenograft assays.
- Luciferase reporter assays to identify regulated pathways.
- Co-immunoprecipitation to determine protein interactions.
Main Results:
- VSIG2 is upregulated in OS tissues resistant to neoadjuvant chemotherapy.
- VSIG2 overexpression confers cisplatin resistance in both cellular and animal models.
- VSIG2 activates the PI3K/AKT/mTOR pathway, leading to increased p70 S6 Kinase phosphorylation.
- Inhibition of mTOR reverses VSIG2-mediated cisplatin resistance.
Conclusions:
- VSIG2 plays a significant role in osteosarcoma chemoresistance.
- VSIG2 confers platinum resistance by activating the PI3K/AKT/mTOR pathway.
- VSIG2 represents a potential therapeutic target for overcoming chemoresistance in OS.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
